secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001326190-25-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q3 net loss $19M ($0.21/sh); cash $210.8M; debt facility upsized to $125M
--------------------------------------------------------------------------------

- Cash and investments $210.8M, up 60% from Dec 2024; net loss $19.0M vs $22.8M year ago.
- Hercules loan amended to $125M; drew additional $20M at close; interest-only period extended to 30 months.
- Phase 2b IMPACT 48-week MASH data expected before year end; End-of-Phase-2 FDA meeting scheduled Q4 2025.
- RECLAIM AUD trial enrollment completed early; topline results expected in 2026. RESTORE ALD trial initiated.
- Appointed CMO (Dr. Arbet-Engels), CCO (Richardson), and CLO (Abrams) to executive team.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/0001326190-25-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/alt-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-25-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer